Hydroxyurea to Prevent CNS Complications of Sickle Cell Disease in Children

Study title

Hydroxyurea to Prevent CNS Complications of Sickle Cell Disease in Children (HU Prevent)

Study objectives

• Conduct a randomized placebo-controlled trial of HU to reduce the CNS complications (abnormal CBFV, SCI and stroke) of SCD
• Determine the safety of study procedures using standardized protocols in toddlers and preschool children with SCD

Eligibility

SCD patients with hemoglobin SS or Sβ0, 9 to 48 months of age, with no history of focal neurologic event, other neurological problems, or currently taking HU.

PI: Dr. Janet Kwiatkowski

SC: Helen Stanley, Jolene Kokroko

Sponsor: National Institutes of Health